Venmax Drugs&Pharma
Ticker > Company >

Venmax Drugs&Pharma share price

Venmax Drugs And Pharmaceuticals Ltd.

BSE: 531015 SECTOR: Pharmaceuticals & Drugs  2.74 K   3   1

31.89
0 0
BSE: 29 Aug 04:01 PM

Price Summary

Today's High

₹ 31.89

Today's Low

₹ 31.89

52 Week High

₹ 36.96

52 Week Low

₹ 6.27

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 16.71 Cr.

Enterprise Value

₹ 17.06 Cr.

No. of Shares

0.52 Cr.

P/E

1392.58

P/B

0

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  -1.2

CASH

₹ 0 Cr.

DEBT

₹ 0.35 Cr.

Promoter Holding

23.13 %

EPS (TTM)

₹  0.02

Sales Growth

0%

ROE

0 %

ROCE

0%

Profit Growth

-71.41 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 YearNA
3 Year-100%
5 Year-100%

Profit Growth

1 Year-71.41%
3 Year33.83%
5 Year17.83%

ROE%

1 Year0%
3 Year0%
5 Year0%

ROCE %

1 Year0%
3 Year0%
5 Year0%

Debt/Equity

-0.5417

Price to Cash Flow

7594.07

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

1.11077897561949

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 23.13 0.00
Mar 2025 23.13 0.00
Dec 2024 23.13 0.00
Sep 2024 23.13 0.00
Jun 2024 23.13 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 0 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.11077897561949.

 Limitations

  • The company has shown a poor revenue growth of -100% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Company has a poor ROCE of 0% over the past 3 years
  • The company has a low EBITDA margin of -50.41386% over the past 5 years.
  • The company has negative book value.
  • The company is trading at a high EV/EBITDA of 837.5263.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 0.1 0.17 0.2 0.33 1.21
Total Expenditure 0.12 0.47 0.69 0.58 1.17
Operating Profit -0.02 -0.3 -0.5 -0.25 0.04
Other Income 0.03 0 0 1.02 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.01 -0.31 -0.5 0.78 0.04
Tax 0 0 0 0 0
Profit After Tax 0.01 -0.31 -0.5 0.78 0.04
Adjusted EPS (Rs) 0.02 -0.58 -0.95 1.49 0.07

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 0.47 0.17 0 0 0
Total Expenditure 0.73 0.5 0.13 0.19 0.1
Operating Profit -0.25 -0.33 -0.13 -0.19 -0.1
Other Income 0 0.18 1.98 0.42 0.2
Interest 0 0 0 0 0
Depreciation 0.01 0.01 0.01 0.01 0.01
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.27 -0.16 1.85 0.23 0.09
Tax 0.01 0 0 0 0.02
Net Profit -0.27 -0.16 1.85 0.23 0.06
Adjusted EPS (Rs.) -0.52 -0.31 3.52 0.43 0.12

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 5.24 5.24 5.24 5.24 5.24
Total Reserves -7.86 -8.03 -6.18 -5.95 -5.89
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 0 0 0
Current liabilities 3.08 3.09 1.15 0.92 0.73
Total Liabilities 0.46 0.31 0.21 0.21 0.08
Assets
Net Block 0.1 0.09 0.08 0.07 0.07
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 0.36 0.22 0.13 0.14 0.02
Total Assets 0.46 0.31 0.21 0.21 0.08
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -0.27 -0.16 1.85 0.23 0.09
Adjustment 0.01 0.01 0.01 0.01 0.01
Changes in Assets & Liabilities -0.03 0.42 0.05 -0.24 -0.07
Tax Paid 0 0 0 0 -0.02
Operating Cash Flow -0.28 0.26 1.91 0 0
Investing Cash Flow 0 0 0 0 0
Financing Cash Flow 0.28 -0.19 -1.98 0 0
Net Cash Flow 0 0.07 -0.07 0 0

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 23.13 23.13 23.13 23.13 23.13
a gopal reddy 0.02 0.02 0.02 0.02 0.02
a ramreddy 0.02 0.02 0.02 0.02 0.02
a venkatasubbaiah 0.02 0.02 0.02 0.02 0.02
aishu finance ltd 0.02 0.02 0.02 0.02 0.02
ambatipudi umapathy 0.03 0.03 0.03 0.03 0.03
anasuyamma chatakonda 0.02 0.02 0.02 0.02 0.02
asha singh 0.02 0.02 0.02 0.02 0.02
b prasad 0.03 0.03 0.03 0.03 0.03
b santhakumar reddy 0.03 0.03 0.03 0.03 0.03
banda shamrao - - - 0.12 0.12
banda usha 0.23 0.23 0.23 0.23 0.23
basava raj 0.02 0.02 0.02 0.02 0.02
bhaskar rao kanakabandi 0.03 0.03 0.03 0.03 0.03
c chalamanaidu 0.02 0.02 0.02 0.02 0.02
ch chalama naidu 0.02 0.02 0.02 0.02 0.02
chandrakala b m 0.02 0.02 0.02 0.02 0.02
d amrutamma 0.05 0.05 0.05 0.05 0.05
d narayana reddy 0.05 0.05 0.05 0.05 0.05
dayanand 0.02 0.02 0.02 0.02 0.02
e narsimhulu 0.02 0.02 0.02 0.02 0.02
g balachandra reddy 0.02 0.02 0.02 0.02 0.02
g mahanandi 0.05 0.05 0.05 0.05 0.05
g naganna 0.03 0.03 0.03 0.03 0.03
g padmaja 0.10 0.10 0.10 0.10 0.10
g sai kumar reddy 0.02 0.02 0.02 0.02 0.02
g sainna 0.04 0.04 0.04 0.04 0.04
golla peddanna 0.02 0.02 0.02 0.02 0.02
gopal gadula 0.04 0.04 0.04 0.04 0.04
gopal yadav gudaula 0.04 0.04 0.04 0.04 0.04
hima bindu 0.02 0.02 0.02 0.02 0.02
j siva kumar 0.05 0.05 0.05 0.05 0.05
j venkata ramana reddy 0.02 0.02 0.02 0.02 0.02
jangayyah 0.02 0.02 0.02 0.02 0.02
jonnadula ravindrababu 0.01 0.01 0.01 0.01 0.01
k chakradhar 0.10 0.10 0.10 0.10 0.10
k indira 0.02 0.02 0.02 0.02 0.02
k kamala kumari 0.02 0.02 0.02 0.02 0.02
k kollappa 0.04 0.04 0.04 0.04 0.04
k kondanna 0.05 0.05 0.05 0.05 0.05
k madhu sudhan 0.02 0.02 0.02 0.02 0.02
k mallaiah 0.02 0.02 0.02 0.02 0.02
k sarojini devi 0.02 0.02 0.02 0.02 0.02
k v parthasaraty 0.05 0.05 0.05 0.05 0.05
k vijaya 0.05 0.05 0.05 0.05 0.05
kanakabandi bhaskara rao 0.02 0.02 0.02 0.02 0.02
karna ramamurthy 0.02 0.02 0.02 0.02 0.02
kishtanna 0.02 0.02 0.02 0.02 0.02
kurava veeranna 0.02 0.02 0.02 0.02 0.02
laxmi prasad 0.02 0.02 0.02 0.02 0.02
lingaih gundeboina 0.02 0.02 0.02 0.02 0.02
m neelakanta reddy 0.04 0.04 0.04 0.04 0.04
m nirmala 0.01 0.01 0.01 0.01 0.01
m p sreenivasa rao 0.02 0.02 0.02 0.02 0.02
m srinivas reddy 0.05 0.05 0.05 0.05 0.05
malathi ravi 0.05 0.05 0.05 0.05 0.05
mohan naidu choppa 0.10 0.10 0.10 0.10 0.10
n achuta bai 1.99 1.99 1.99 1.99 1.99
n jyothi kiran 0.10 0.10 0.10 0.10 0.10
n narasa reddy 0.02 0.02 0.02 0.02 0.02
n nirmala 0.05 0.05 0.05 0.05 0.05
n shantamma 0.05 0.05 0.05 0.05 0.05
nagaiah 0.02 0.02 0.02 0.02 0.02
nagendra babu s 0.01 0.01 0.01 0.01 0.01
nand kumar murari 0.05 0.05 0.05 0.05 0.05
naresh v 0.05 0.05 0.05 0.05 0.05
p n tatarao 0.05 0.05 0.05 0.05 0.05
p rajeshwari 0.02 0.02 0.02 0.02 0.02
padma raghunathan 0.02 0.02 0.02 0.02 0.02
padmanabha reddy p 0.02 0.02 0.02 0.02 0.02
peta balappa 0.04 0.04 0.04 0.04 0.04
poorna chandar p 0.02 0.02 0.02 0.02 0.02
r padmavatamma 0.05 0.05 0.05 0.05 0.05
ram reddy 0.02 0.02 0.02 0.02 0.02
ramana b 0.02 0.02 0.02 0.02 0.02
ravi shankar 0.02 0.02 0.02 0.02 0.02
s kistaiah 0.02 0.02 0.02 0.02 0.02
s sambasiva reddy 0.02 0.02 0.02 0.02 0.02
s subbi reddy 0.02 0.02 0.02 0.02 0.02
saivaiah soma 0.02 0.02 0.02 0.02 0.02
satyanarayan reddy k 0.02 0.02 0.02 0.02 0.02
sharat kumar reddy 0.02 0.02 0.02 0.02 0.02
shernaz omim debara 0.02 0.02 0.02 0.02 0.02
sitaiah b 0.02 0.02 0.02 0.02 0.02
soma tripura 0.02 0.02 0.02 0.02 0.02
sree rama reddy 0.02 0.02 0.02 0.02 0.02
sreenivasa rao v 0.02 0.02 0.02 0.02 0.02
srinivasulu vegendla 0.02 0.02 0.02 0.02 0.02
srinu k 0.02 0.02 0.02 0.02 0.02
sukanya murari setty 0.02 0.02 0.02 0.02 0.02
t devasena 0.05 0.05 0.05 0.05 0.05
t triveni 0.04 0.04 0.04 0.04 0.04
tirupathi reddy 0.02 0.02 0.02 0.02 0.02
uttam kishinchand jethwan... 0.03 0.03 0.03 0.03 0.03
v chandra mouli 0.02 0.02 0.02 0.02 0.02
v ramadevi 0.02 0.02 0.02 0.02 0.02
venkat narender nuka 17.69 17.69 17.69 17.69 17.69
venkata swarajya vijaya l... 0.02 0.02 0.02 0.02 0.02
venkatarama reddy 0.02 0.02 0.02 0.02 0.02
venkateswara rao g 0.02 0.02 0.02 0.02 0.02
y sai ram 0.02 0.02 0.02 0.02 0.02
y sambasiva reddy 0.02 0.02 0.02 0.02 0.02
shamrao banda 0.12 0.12 0.12 - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 76.87 76.87 76.87 76.87 76.87
asset reconstruction comp... 1.91 1.91 1.91 1.91 1.91
dr tadla tirumal rao - - 5.72 5.44 5.15
durga dairy limited - - 1.91 1.91 1.91
j muralidharan 3.82 3.82 3.82 3.82 3.82
musty prabhakar . - - 1.79 1.79 1.79
percy homi italia 12.72 12.72 8.90 8.90 8.90
r jagadish kumar 1.91 1.91 1.91 1.91 1.91
roshan sethia 2.29 2.29 2.29 2.29 1.32
sanjay p parikh - - - - 1.34
samta polymers ltd - - - 1.01 -
sudhanshu kanda - - - 1.20 -
kanakabandi venkat sudhee... - - 2.02 - -
umapathi vavilala 1.15 1.15 1.15 - -
kanakabandi venkat sudhee... 2.02 2.02 - - -
musty prabhakar 1.79 1.79 - - -
raj kumar rai 5.73 5.73 - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Venmax Drugs & Pharmaceuticals submits unaudited standalone financial results 23 Jul, 4:39 PM Venmax Drugs&Pharma - Quaterly Results 23 Jul, 3:41 PM Venmax Drugs&Pharma - Quaterly Results 23 Jul, 3:41 PM Venmax Drugs&Pharma - Quaterly Results 23 Jul, 3:41 PM Venmax Drugs and Pharmaceuticals informs about board meeting 16 Jul, 3:25 PM Venmax Drugs&Pharma - Quaterly Results 9 May, 1:31 PM Venmax Drugs&Pharma - Quaterly Results 9 May, 1:31 PM Venmax Drugs&Pharma - Quaterly Results 9 May, 1:31 PM Venmax Drugs and Pharmaceuticals informs about disclosure 5 May, 5:22 PM Venmax Drugs & Pharmaceuticals informs about newspaper advertisement 10 Feb, 5:25 PM Venmax Drugs&Pharma - Quaterly Results 8 Feb, 3:07 PM Venmax Drugs&Pharma - Quaterly Results 8 Feb, 3:07 PM Venmax Drugs&Pharma - Quaterly Results 8 Feb, 3:07 PM Venmax Drugs&Pharma - Quaterly Results 11 Nov, 3:37 PM Venmax Drugs And Pharmaceuticals informs about financial results 17 Sep, 2:03 PM Venmax Drugs and Pharmaceuticals informs about resignation of independent director 10 Sep, 5:38 PM Venmax Drugs&Pharma - Quaterly Results 12 Aug, 5:35 PM Venmax Drugs&Pharma - Quaterly Results 12 Aug, 5:35 PM Venmax Drugs&Pharma - Quaterly Results 14 May, 12:00 PM Venmax Drugs&Pharma - Quaterly Results 14 May, 12:00 PM Venmax Drugs&Pharma - Quaterly Results 30 Jan, 1:51 PM Venmax Drugs&Pharma - Quaterly Results 30 Jan, 1:51 PM Venmax Drugs&Pharma - Quaterly Results 30 Jan, 1:51 PM Venmax Drugs And Pharmaceuticals informs about certificates 13 Nov, 5:11 PM Venmax Drugs and Pharmaceuticals informs about disclosure 21 Oct, 3:35 PM Venmax Drugs&Pharma - Quaterly Results 15 May, 6:00 PM Venmax Drugs&Pharma - Quaterly Results 15 May, 6:00 PM Venmax Drugs and Pharmaceuticals informs about revised outcome of board meeting 18 Feb, 1:52 PM Venmax Drugs&Pharma - Quaterly Results 30 Jan, 4:53 PM Venmax Drugs&Pharma - Quaterly Results 30 Jan, 4:53 PM Venmax Drugs&Pharma - Quaterly Results 30 Jan, 4:53 PM Venmax Drugs and Pharmaceuticals informs about un-audited financial results 6 Dec, 5:23 PM Venmax Drugs&Pharma - Quaterly Results 4 Nov, 4:46 PM Venmax Drugs&Pharma - Quaterly Results 4 Nov, 4:46 PM Venmax Drugs&Pharma - Quaterly Results 4 Nov, 4:46 PM Venmax Drugs and Pharmaceuticals informs about scrutinizers report 3 Oct, 4:36 PM Venmax Drugs&Pharma - Quaterly Results 30 Jul, 4:48 PM Venmax Drugs&Pharma - Quaterly Results 30 Jul, 4:48 PM Venmax Drugs&Pharma - Quaterly Results 30 Jul, 4:48 PM

Venmax Drugs&Pharma Stock Price Analysis and Quick Research Report. Is Venmax Drugs&Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Venmax Drugs&Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Venmax Drugs&Pharma has a PE ratio of 1392.57641921397 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Venmax Drugs&Pharma has ROA of 44.0574% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Venmax Drugs&Pharma has a Current ratio of 0.0215.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Venmax Drugs&Pharma has a ROE of 0%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Venmax Drugs&Pharma has a Debt to Equity ratio of -0.5417 which means that the company has low proportion of debt in its capital.

  • Sales growth: Venmax Drugs&Pharma has reported revenue growth of 0% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Venmax Drugs&Pharma for the current financial year is 0%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Venmax Drugs&Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Venmax Drugs&Pharma is Rs 0.0229. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Venmax Drugs&Pharma in Ticker for free. Also, one can get the intrinsic value of Venmax Drugs&Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Venmax Drugs&Pharma FAQs

Q1. What is Venmax Drugs&Pharma share price today?
Ans: The current share price of Venmax Drugs&Pharma is Rs 31.89.

Q2. What is the market capitalisation of Venmax Drugs&Pharma?
Ans: Venmax Drugs&Pharma has a market capitalisation of Rs 16.70694777 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Venmax Drugs&Pharma?
Ans: The PE ratio of Venmax Drugs&Pharma is 1392.57641921397 and the P/B ratio of Venmax Drugs&Pharma is -26.603820805873, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Venmax Drugs&Pharma share?
Ans: The 52-week high share price of Venmax Drugs&Pharma is Rs 36.96, and the 52-week low share price of Venmax Drugs&Pharma is Rs 6.27.

Q5. Does Venmax Drugs&Pharma pay dividends?
Ans: Currently, Venmax Drugs&Pharma does not pay dividends. Dividend yield of Venmax Drugs&Pharma is around 0%.

Q6. What are the face value and book value of Venmax Drugs&Pharma shares?
Ans: The face value of Venmax Drugs&Pharma shares is Rs 10, while the book value per share of Venmax Drugs&Pharma is around Rs -1.1987. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Venmax Drugs&Pharma?
Ans: Venmax Drugs&Pharma has a total debt of Rs 0.3521 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Venmax Drugs&Pharma?
Ans: The ROE of Venmax Drugs&Pharma is 0% and ROCE of Venmax Drugs&Pharma is 0%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Venmax Drugs&Pharma a good buy for the long term?
Ans: The Venmax Drugs&Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Venmax Drugs&Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Venmax Drugs&Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Venmax Drugs&Pharma’s financials?
Ans: You can review Venmax Drugs&Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Venmax Drugs&Pharma
X